Tranquillisation or asleep · psychosis‐induced aggression or agitation (rapid tranquillisation)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Repeated need for tranquillisation ‐ not reported · psychosis‐induced aggression or agitation (rapid tranquillisation)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Specific behaviour: Agitation ‐ clinically important change (PANSS ‐EC reduction ≥ 40% from baseline) ‐ up to 2 hours · psychosis‐induced aggression or agitation (rapid tranquillisation)
ARIPIPRAZOLE (IM) may leads to lower specific behaviour: Agitation ‐ clinically important change (PANSS… compared with OTHER ANTIPSYCHOTIC: b. OLANZAPINE (low certainty).
1 finding from 1 review
Global state: CGI‐S change score up to 2 hours · psychosis‐induced aggression or agitation (rapid tranquillisation)
1 finding from 1 review
Adverse effects: one or more adverse effects during 24 hours · psychosis‐induced aggression or agitation (rapid tranquillisation)
It is very uncertain whether ARIPIPRAZOLE (IM) changes adverse effects: one or more adverse effects during 24 hours compared with OTHER ANTIPSYCHOTIC: b. OLANZAPINE (very low certainty).
1 finding from 1 review
Somnolence · psychosis‐induced aggression or agitation (rapid tranquillisation)
ARIPIPRAZOLE (IM) may leads to lower adverse effects: somnolence during 24 hours compared with OTHER ANTIPSYCHOTIC: b. OLANZAPINE (low certainty).
1 finding from 1 review
Economic outcomes · psychosis‐induced aggression or agitation (rapid tranquillisation)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Global outcome: need for additional measures · psychosis‐induced aggression or agitation (rapid tranquillisation)
It is very uncertain whether RISPERIDONE changes global outcome: need for additional measures compared with OTHER ANTIPSYCHOTIC: b. OLANZAPINE (very low certainty).
1 finding from 1 review
Adverse effects ‐ movement disorders · psychosis‐induced aggression or agitation (rapid tranquillisation)
1 finding from 1 review
Economic outcomes ‐ not measured · psychosis‐induced aggression or agitation (rapid tranquillisation)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Tranquillisation or asleep by 30 minutes ‐ not measured · psychosis‐induced aggression or agitation (rapid tranquillisation)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Repeated need for tranquillisation ‐ not reported · psychosis‐induced aggression or agitation (rapid tranquillisation)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Specific behaviour ‐ agitation · psychosis‐induced aggression or agitation (rapid tranquillisation)
1 finding from 1 review
Subjective well‐being · people with both severe mental illness and substance misuse
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Craving · people with both severe mental illness and substance misuse
1 finding from 1 review
Adherence to antipsychotic medication: number of missed doses, average endpoint data, short term (up to 6 months) · people with both severe mental illness and substance misuse
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects: Parkinsonism ‐ average endpoint score (SAS, high = worse) · people with both severe mental illness and substance misuse
1 finding from 1 review
Leaving the study early · people with both severe mental illness and substance misuse
It is very uncertain whether RISPERIDONE changes leaving study early: any reason compared with OLANZAPINE ‒ short‐ and long‐term data (very low certainty).
1 finding from 1 review
Mental state: 2. Specific‐ Positive symptoms, total score‐ average endpoint scores (SADS‐C‐PD scale, lower = better) · people with both severe mental illness and substance misuse
1 finding from 1 review
Substance use: 1. Reduction of cannabis use‐change data (number of joints smoked/week) · people with both severe mental illness and substance misuse
1 finding from 1 review